AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04839016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314
Study NCT04839016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05217160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KeraStat® Gel with Morphine application
Description: Administration and application of KeraStat® Gel with Morphine (Bi-Weekly):~KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.
Study NCT05217160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KeraStat® Gel application
Description: Administration and application of KeraStat® Gel (Bi-Weekly):~Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject.~Home Administration and application of KeraStat® Gel (Every 1-3days):~Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes.
Study NCT06194214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.
Study NCT06194214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered Orally.
Study NCT04709042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chordal tension measurement
Description: The chordal tension measurement will be performed during surgery. The neochordae are connected to the measuring device through crocodile clips (e.g. machine-patient interface).We start to apply traction on the chordae that is in the center of the flailing area thanks to a millimeter screw and under TEE control. After obtaining a stable tension (plateau value), the other chordae are then tracked, one at a time, with an individual screw. When we achieve an equivalent tension on all chordae, a traction on all chordae is applied thanks to the principal screw under TEE control until obtaining a perfect coaptation. When the correction is optimal (good echocardiographic result, chordal tension low and equally spread on each chordae), the measurements are then stopped, and the chordae are fixed at the apex of the left ventricle at the optimal length.
Study NCT04709042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (MRI)
Description: Patients will undergo 2 MRI exams: 1 MRI before surgical intervention (maximum 21 days before) and 1 MRI three months after surgery (+/- 14 days), with intravenous administration of gadolinium.
Study NCT04929535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen Peroxide 30 % Topical Solution
Description: Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
Study NCT04929535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide 30 % Topical Solution
Description: Patients will be seen by the radiation therapists involved with the study after randomization. Prior to application of hydrogen peroxide solutions, the patients' lesions will be prepared and debrided of keratinous debris and oils using sterile 70% isopropyl alcohol. Then, the appropriate hydrogen peroxide solution (30% for Arm 1 or 3% for Arm 2) will be rubbed into the lesion and a 1cm border all around the lesion until blanching of the lesion is observed. Hydrogen peroxide will be reapplied after one hour. This process will be repeated weekly for three additional applications for this study. If there is complete clinical response, further hydrogen peroxide will not be done. Patients will be accessed for definitive treatment 4 weeks later.
Study NCT05832697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid 250 Mg Oral Tablet
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
Study NCT06288048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching + MFT
Description: Experimental:~Target: Proximal third of m. Brachioradialis (BR) Patient position: Seated Therapist position: Same side as needle insertion Needle insertion direction: Lateral-to-medial towards clinician\&#39;s finger Needle type: AguPunt® Barcelona, Spain Technique: Seek three local twitch responses in m. Brachioradialis (BR) Alternative for no responses: 10 needle insertions and withdrawals at 1 Hz frequency~Ischemic Compression (IC):~Applied using sphygmomanometer on seated subject\&#39;s arm Pressure: Increased until ischemic pain (approx. 200 mmHg) Duration: Maintained for 90 seconds~Combined with three applications of Cryos Phyto Performance 400 ml cold spray synchronized with m. Brachioradialis (BR) stretching:~Stretching: Passive sustained mobilization with elbow extension and forearm pronation for 10 seconds~Mirror Therapy (MFT):~Setup: Patient seated with forearms resting on bed Mirror: 35 x 35 cm, covering punctured side at 45-degree angle for hand visualization
Study NCT06288048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Dry Needling (DDN), Ischemic Compression, Cold Spray with Stretching
Description: The intervention protocol in this study will target individuals experiencing Post-needling pain associated with lateral elbow pain. It will comprise a series of treatments including Deep Dry Needling (DDN) focused on the proximal third of the m. Brachioradialis (BR), conducted with the patient seated and the therapist positioned on the same side as the needle insertion. Following DDN, ischemic compression (IC) will be applied using a sphygmomanometer on the seated subject\&#39;s arm, along with three applications of cold spray synchronized with m. Brachioradialis (BR) stretching. The intervention will not conclude with Mirror Therapy (MFT).
Study NCT05042492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gekoTM
Description: The gekoTM device is a small, transcutaneous nerve stimulator that is placed non-invasively on the skin, whereby the surface electrodes will be attached close to the peroneal nerve. Activation of the peroneal nerve causes contraction of the calf muscle pump, which will increase blood circulation that corresponds to 60% of walking. The increased blood circulation reduces the pressure difference between capillaries and the surrounding tissue and transfers the tissue fluid back into the veins and lymph fibers
Study NCT05565937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BL-3100-NBR03 multi-purpose solution
Description: BL-3100-NBR03 multi-purpose solution used to clean and disinfect contact lenses
Study NCT05565937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: renu® Advanced Formula multi-purpose solution
Description: renu® Advanced Formula multi-purpose solution used to clean and disinfect contact lenses
Study NCT05998967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Mantram Repetition Program
Description: Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
Study NCT05998967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mantram Repetition Program
Description: Internet-based instruction in a meditation practice that involves silent repetition of a spiritual word, one-pointed attention and slowing down
Study NCT06091514 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CS Medical Watch
Description: The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
Study NCT06091514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specific questionnaire
Description: Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)
Study NCT05413772 — intervention group
Intervention type: OTHER
Intervention: Temocillin
Description: To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections
Study NCT05512559 — intervention group
Intervention type: DEVICE
Intervention: body composition analysis
Description: Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
Study NCT05627687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate Variability Biofeedback
Description: Practice using the Inner Balance app and device, 10 minutes/day, 4-5 days per week
Study NCT05627687 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Music Listening Control
Description: Listening to music using the Coffeehouse playlist on either Pandora or Spotify app, 10 minutes/day, 4-5 days per week
Study NCT05670015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dosage selective alpha-2 receptor agonists topical eyedrop
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
Study NCT05670015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dosage selective alpha-2 receptor agonists topical eyedrop
Description: Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
Study NCT06486701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: have a sing
Description: Singing
Study NCT06216496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dynamic test for amino acid metabolism
Description: Subjects are fasting, and the dynamic test is performed as follows:~Placement of 1 peripheral venous line (for infusions).~* H0-H1.5: infusion of a 10% glucose solution at increasing flow rate (3 steps of 30 min each: 0.06g/kg/h then 0.12g/kg/h then 0.25g/kg/h of glucose)~* H1,5: initial blood sampling (amino acid assay)~* H1.5-H4.5: infusion of amino acid solution (Aminoven 5%, Fresenius Kabi, Sèvres, France) at constant speed (flow rate 10.5 mg/kg/h of nitrogen or 1.30 ml/kg/H) in Y with glucose infusion (0.25g/kg/h of glucose)~* H4.5: Final blood sampling (amino acid assay) Each amino acid is plotted as a function of its perfusion rate on the abscissa and its variation in plasma concentration on the ordinate.
Study NCT06262074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise Program
Description: 30 minutes of structured exercise programs
Study NCT06262074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non structured exercise program
Description: Non structured exercises
Study NCT06231524 — intervention group
Intervention type: OTHER
Intervention: Analyse pathologic slides
Description: HE-stained whole slide images were used for the validation of the PSN-AI model.
Study NCT05460455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo
Description: HB0034 and Placebo
Study NCT05793008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) analysis
Description: 18F-FDG-PET/CT imaging will be performed 3 months after the acute event at the Department of Nuclear Medicine of Fondazione Policlinico Universitario A. Gemelli IRCCS using an integrated scanner. Intravenous 18F-FDG (370 MBq) will be given following an overnight fast. Three-dimensional PET imaging will be performed after 1 h of quiet waiting. A non-gated, non-contrast CT will be acquired for attenuation correction. Brain structures analyzed will include the neocortex, limbic system (insula, amygdala, cingulate cortex, and hippocampus), reticular formation, brainstem, and spinal cord.
Study NCT05793008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples collection
Description: At the time of coronary angiography for patients with primary or secondary TTS and within the first 48 hours for patients with sepsis or septic shock, arterial blood samples will be collected in 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes. Furthermore, a hair sample of 6 cm will be collected for hair cortisol assay.~For patients with primary or secondary TTS blood samples will be collected by venipuncture with 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes also at 3 months follow-up.~Blood samples will be immediately centrifuged to obtain whole blood, serum, and plasma samples, and then aliquoted into Eppendorf-type tubes. All samples will then be stored at -80°C until the analysis.
Study NCT05793008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow up visit
Description: Participation in this study requires for patients with primary vs secondary TTS, a follow-up visit at 3 months (90 +/- 5 gg) after enrollment to assess a Positron Emission Tomography (PET) analysis, and during the same visit, venous blood sampling as described above will be further performed.
Study NCT05616000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine, folic acid
Description: Acetyl-l-carnitine 2gm once a day\& folic acid will be given to 43 primary infertile men
Study NCT06235567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
Study NCT06235567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical prednisolone acetate 1% (PredForte) eye drops
Description: The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
Study NCT06000124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: High knee lifts, squat jumps, lunge cross jumps, squat jumping lunges, and squat jump twists are examples of plyometric exercises suitable for older adults.
Study NCT06341660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
Study NCT05681689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PyloPlus UBT System
Description: Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
Study NCT05681689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histology
Description: Biopsy specimen fixed with 10% buffered formalin cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist.
Study NCT05681689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid Urease Test
Description: Biopsy specimen obtained and placed onto Rapid Urease Test
Study NCT05681689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comparator Breath Test
Description: Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
Study NCT05681689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool Antigen Test
Description: An antigen test performed via a laboratory to test patient's stool for H. pylori
Study NCT03567824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium L-lactate dihydrate
Description: Magnesium L-lactate dihydrate 10 mEq extended release caplets
Study NCT03567824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium L-lactate dihydrate
Description: Magnesium L-lactate dihydrate 10 mEq extended release caplets
Study NCT03567824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
Study NCT05369195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC procedure with the use of transcatheter cerebral protection system
Description: After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
Study NCT05369195 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: LAAC procedure without the use of transcatheter cerebral protection system
Description: Only the aortography through radial access will be done before accessing the left atrium.
Study NCT05512975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein porridge arm
Description: Regular porridge ingredients with additional delical whey protein fortification
Study NCT05512975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant protein porridge arm
Description: Regular porridge ingredients with the addition of extruded soya protein fortification and soya milk instead of regular dairy milk
Study NCT05512975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Porridge arm
Description: Regular porridge ingredients with no additional protein fortification
Study NCT05230836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency alternating current stimulation
Description: For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 30 kHz, 40 kHz and 50 kHz will be applied. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the excitomotor threshold on the palmar aspect of the hand in the dermatomes innervated by the median nerve. The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol has been used in previous studies conducted by our research group
Study NCT05230836 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham current stimulation
Description: Sham electrical stimulation will be performed with the same equipment and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) is exceeded and once the threshold is reached, the intensity will be reduced to 0 mA with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants.
Study NCT06000124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regulation Exercises Program
Description: The regulated exercise program includes the use of elastic bands, Qigong, and dance et al.
Study NCT04474509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT Module Engagement
Description: Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
Study NCT04474509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT Module Openness
Description: Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
Study NCT04474509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT Module Awareness
Description: Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
Study NCT05253989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Intervention
Description: VR Device that allows a patient to play games based on the EMG activity in the upper limb.
Study NCT05253989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FES
Description: Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
Study NCT04677179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: administered SC
Study NCT04677179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3471851
Description: administered SC
Study NCT04677179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered SC
Study NCT04472000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
Study NCT04472000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.